Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board

Leading experts in cytometry science, laboratory medicine, and cancer research from the University of Pennsylvania, New York Blood Center, and Amgen strengthen Nodexus’ scientific leadership

SAN JOSE, Calif.--()--Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB). The Nodexus SAB is chaired by Professor Jonni Moore, PhD, one of the world’s leading experts in flow cytometry, laboratory medicine, and cellular immunology.

The SAB will provide strategic direction and guidance for commercial expansion and product innovation to help Nodexus on its mission to accelerate cell biology workflows and make them universally accessible. Nodexus’ NX One single-cell isolation system is quickly emerging as a critical component for cell line and antibody development, CRISPR and protein engineering, synthetic biology, and single-cell genomics, among other rapidly growing applications, and the company’s SAB aims to accelerate further adoption of Nodexus platforms.

“We are excited to have some of the world’s foremost experts in cytometry join our SAB, and we are confident that the breadth of knowledge that Jonni, John, and Peter bring to Nodexus will enable us to drive innovation for single-cell workflows,” said Karthik Balakrishnan, PhD, Founder and CEO of Nodexus. “With the support of our SAB, we’re dedicated to providing advanced capabilities and value to scientists – all at a price that every lab can afford. Our stellar group of scientific advisors will lead us in providing transformational advancements in cell biology.”

The new members of the SAB include:

Chairperson: Jonni S. Moore, PhD – Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania and the Perelman School of Medicine. Dr. Moore has pioneered new technology in flow cytometry liquid biopsies, including the detection of extracellular vesicles as a rich source of prognostic and diagnostic information and developing this technology for diagnostics / prognostics in cardiovascular disease, traumatic brain injury, and relapsing breast cancer. More recently, she has focused on the development of high dimensional deep phenotyping approaches for the identification of biomarkers of cancer responses using advanced analytical technologies. In addition to her academic positions, Dr. Moore is widely known for her work as the former President of the International Society of Cytometry (ISAC).

Peter A. Lopez – Vice President, Technical Operations and Innovations, New York Site Head, Comprehensive Cell Solutions, New York Blood Center and Associate Professor in the Department of Pathology at the New York University Grossman School of Medicine. Mr. Lopez has been a leading innovator in the field of flow cytometry for over four decades, and his focus has been to help facilitate the use of cytometry to answer critical biological questions such as the impacts of sorter-induced cellular stress (SICS) and its detrimental effects on the processes of cellular metabolism. He has applied his extensive cytometric expertise to a wide range of studies, including the automated detection of malignant or premalignant cells, hematopoietic stem cell isolation, the study of T-cell receptor function, the detection and study of apoptotic cells, and the investigation of HIV infection in varied cell types. Mr. Lopez currently oversees technical operations for the manufacturing of innovative cell therapeutics.

John Ferbas, PhD – Director, Cytometry Sciences at Amgen, Inc. Dr. Ferbas has had a highly distinguished career in the pharmaceutical industry, leveraging cutting-edge technologies for cellular characterization and isolation, as well as advancing educational outreach programs that contribute to innovation. He has a 25+ year tenure at Amgen and currently serves as a Director in the Department of Discovery Biological Sciences for therapeutic discovery and precision biology. Prior to Amgen, Dr. Ferbas was an Assistant Professor of Medicine at the University of California, Los Angeles School of Medicine. He is a founding member of the Southern California Flow Cytometry Association (SoCal Flow) and the American Association of Pharmaceutical Scientists (AAPS) PharmaFlow Working Group.

“I’m extremely pleased to serve as the Chairperson of Nodexus’ Scientific Advisory Board,” said Dr. Moore. “The technological innovation that Nodexus has developed to simplify and democratize single-cell sorting and dispensing has the potential for far-ranging impact across translational research and the pharma and biotech industries. I look forward to working with my distinguished SAB colleagues, Nodexus’ senior leadership and Board of Directors, and its talented R&D and commercial teams to develop and deploy cost-effective technology platforms to accelerate scientific discovery and cell biology workflows globally.”

About Nodexus

Nodexus is a life science tools company that develops platforms to accelerate biological workflows and make them widely accessible. The company leverages a proprietary technology suite consisting of contamination-free microfluidic cartridges, hardware instruments, and software offerings. Nodexus’ flagship NX One platform offers integrated, easy-to-use, and affordable automated cell isolation for applications in industry, clinical research, and academia, including cell line and antibody development, CRISPR engineering, single-cell genomics, synthetic biology, and more. For more information regarding the company and the NX One, please visit Nodexus.


Anthony Petrucci